Cannabis
Elixxer Ltd. Announces New Director
Montreal, Quebec–(Newsfile Corp. – November 26, 2021) – Elixxer Ltd. (TSXV: ELXR) (OTCQB: ELIXF) (the “Corporation” or “Elixxer“) is pleased to announce that Mr. Jeremy Green has been appointed to the Corporation’s board of directors. Mr. Green is replacing Mr. Jeff Cheah who has resigned due to health reasons.
Mr. Green’s career spans over twenty years in the banking industry. Until recently, he was senior director for online and mobile banking with a major Canadian chartered bank. Prior to that, he spent ten years with a competing Canadian chartered bank where he worked on numerous large scale retail banking projects, both in North America and in Europe. In addition, he has been a leading speaker on digital banking strategies at numerous industry conferences. Mr. Green holds a bachelor’s degree in administration from Simon Fraser University and an MBA in finance from Wilfrid Laurier University. Mr. Green’s appointment is subject to acceptance by the TSX Venture Exchange.
About Elixxer Ltd. (www.elixxer.com)
Elixxer Ltd. is a Canadian public company listed on the TSX Venture Exchange (TSXV: ELXR) and the US OTCQB exchange (OTCQB: ELXIF).
Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy, and Canada.
For further information please contact:
Ferras Zalt, Chairman and Interim CEO: +44 20 7409 6680; [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105215
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis1 day ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Cannabis2 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical